Groundbreaking study demonstrates that targeted oligodendrocyte gene therapy leads to decreased N-acetylaspartate (NAA) levels and increased brain myelin volume, resulting…
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company…
Phase 1 study to progress to the next dose level of 75mCi in patients with HER2+ advanced solid tumors, instead…
CHARLESTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic…
TORONTO, Sept. 30, 2025 /PRNewswire/ -- Creyos, the digital platform reshaping brain health assessment in clinical care, is thrilled to announce…
The gold-standard dataset will power a new generation of AI tools to forecast Alzheimer's risk, track progression, and guide interventions…
- Clinical study conducted at the Dementia Research Centre, Nanyang Technological University, Singapore, involving Southeast Asian participants - Expert level accuracy,…
Leveraging MaxYield™ ECG to capture real-world exercise data in people living with neurological conditionsGenerating actionable insights into how cardiac responses…
Publication title: “Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of…
CLOVER-2 Phase 1 Clinical Study Evaluating Iopofosine I 131 in Relapsed/Refractory Pediatric High-Grade Glioma Patients Showed Extended Progression-Free Survival and…